Results 1 to 10 of about 7,605 (170)

Expression of poly(Adenosine Diphosphate-Ribose) polymerase protein in breast cancer [PDF]

Journal of Mid-Life Health, 2022
Background: The use of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors for breast cancer (BC) therapy is the subject of debate, and there is an urgent need to understand much the expression and prognostic role of the PARP1 protein.
Akanksha, Shashi Prakash Mishra, Amrita Ghosh Kar, J S Karthik, Aviral Srivastava, Rahul Khanna, Ram Niwas Meena   +6 more
doaj   +4 more sources

Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy [PDF]

Biomolecules, 2012
Treatments with Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors have offered patients carrying cancers with mutated BRCA1 or BRCA2 genes a new and in many cases effective option for disease control.
Thomas Helleday, Cecilia E. Ström
doaj   +4 more sources

Poly(Adenosine Diphosphate–Ribose) Polymerase Inhibitors in Cancer Treatment [PDF]

Hematology/Oncology Clinics of North America, 2012
Recently, the development of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors as a synthetic lethality approach has brought a major breakthrough in the treatment of breast cancer susceptibility gene (BRCA)-mutant cancers. Because sporadic cancers have also been found to commonly have other defects in DNA repair, PARP inhibitors are under

exaly   +5 more sources

Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors in Pancreatic Cancer. [PDF]

Cureus, 2022
Pancreatic cancer is the third most common cause of cancer death in the United States and eleventh worldwide. The majority of patients present with advanced disease with five-year overall survival of less than 10%. Traditional chemotherapy has been the mainstay treatment for years, with limited improvement in survival.
Sunkara T, Bandaru SS, Boyilla R, Kunadharaju R, Kukkadapu P, Chennamadhavuni A.   +5 more
europepmc   +4 more sources

Vascular Protection of Poly(ADP-ribose) Polymerase Inhibitors in the Combination Therapy With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors [PDF]

Reviews in Cardiovascular Medicine
The Poly(ADP-ribose) polymerase (PARP) family comprises seventeen members that catalyze poly- or mono- adenosine diphosphate (ADP)-ribosylation, a pivotal post-translational modification regulating a wide array of cellular processes, including ...
Jie Ma, Caie Li, Wenjuan Wang, Xin Fan, Taotao Wei, Xin Ma, Yingdong Wang, Chuyan Feng, Jing Yu   +8 more
doaj   +2 more sources

Prognostic and clinicopathological value of poly (adenosine diphosphate-ribose) polymerase expression in breast cancer: A meta-analysis. [PDF]

PLoS ONE, 2017
BACKGROUND:Previous studies have shown that the poly (adenosine diphosphate-ribose) polymerase (PARP) level is a promising indicator of breast cancer. However, its prognostic value remains controversial. The present meta-analysis evaluated the prognostic
Weiqiang Qiao, Linlin Pan, Changgui Kou, Ke Li, Ming Yang   +4 more
doaj   +2 more sources

Natural occurence of a biopolymer, poly (adenosine diphosphate ribose)

Nucleic Acids Research, 1977
Evidence for the natural occurrence of poly(adenosine diphosphate ribose) in vivo was obtained using a sensitive radioimmunoassay and poly(adenosine diphosphate ribose) glycohydrolase, which specifically hydrolyzes poly(adenosine diphosphate ribose).
Masanao Miwa, Sugimura T, Shimada T
exaly   +4 more sources

Model for Predicting Serious Hematological Adverse Events in Individuals With Ovarian Cancer Receiving Poly (Adenosine Diphosphate Ribose) Polymerase Inhibitor Treatment: Prospective Cohort Study [PDF]

JMIR Medical Informatics
BackgroundPredicting serious hematological adverse events (SHAEs) from poly (adenosine diphosphate ribose) polymerase inhibitors (PARPis) would allow us to prioritize patients with ovarian cancer at higher risk for more intensive ...
Xiaotong Lian, Yu Lei
doaj   +2 more sources

Latin American Challenges and Recommendations for Poly Adenosine Diphosphate Ribose Polymerase Inhibitor Treatment in Metastatic Castration Resistant Prostate Cancer: An Expert Overview [PDF]

Cancer Control
In Latin America, prostate cancer is the third most common cancer overall and the most common in men, with the highest mortality rate of all cancers.
Rodolfo Borges dos Reis MD, PHD, José L. Aguilar-Ponce MD, Federico Cayol MD, MSc, Angela M. Jansen PhD, MHS, Ray Manneh K MD, MSc, Tomas R Merino MD, Gayatri Sanku PhD, MPH, Laura B. Vaca MD, Pedro Isaacsson Velho MD, Ernesto P. Korbenfeld MD   +9 more
doaj   +2 more sources

Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition [PDF]

Pharmacogenomics and Personalized Medicine, 2014
M William Audeh Division of Medical Oncology, Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA Abstract: Inhibitors of the poly(adenosine triphosphate-ribose) polymerase (PARP)-1 enzyme induce synthetic lethality in ...
Audeh MW
doaj   +2 more sources